Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
208 participants
OBSERVATIONAL
2022-01-13
2022-09-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating the Response of the Immune System of People with Long COVID (post SARS-CoV-2)
NCT05131594
Predictive Markers of the Course of Covid-19 Based on Biomarker Serum Amyloid A (SAA) and Genetic Markers
NCT07120269
Hematological Disorders in Covid 19 Patients
NCT05182528
Investigating Development of Autoimmunity in Post-Acute COVID-19 Syndrome (PACS)
NCT05459506
Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
NCT05669677
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cases
Individuals at age 18 to 65 with a SARS-CoV-2 infection proven by a polymerase chain reaction (PCR) test at least 12 weeks prior to inclusion and who have been referred to the clinic of post-COVID conditions.
No interventions assigned to this group
Controls
Healthy volunteers at age 18 to 65 with a SARS-CoV-2 infection proven by a PCR test at least 12 weeks prior to inclusion.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* SARS-CoV-2 infection proven by a PCR test at least 12 weeks prior to inclusion
* Only cases: Referred to the Clinic of post-COVID conditions located in Region Zealand, Denmark
Exclusion Criteria
* Only controls: complain about long covid 12 weeks or more after proven infection with SARS-CoV-2
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mental Health Services in the Capital Region, Denmark
OTHER
Skane University Hospital
OTHER
Zealand University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gesche Jürgens, Associate Professor, Ph.D., MD
Role: STUDY_DIRECTOR
Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark
Thomas Werge, Professor, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Institute of Biological Psychiatry, Sct. Hans Hospital, Capital Region, Denmark
Fredrik Kahn, Associate Professor, Ph.D., MD
Role: PRINCIPAL_INVESTIGATOR
Department of infectious disease, Skåne University Hospital, Sweden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zealand University Hospital
Roskilde, Region Sjælland, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SJ-947 (EMN-2021-07028)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.